Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Coeptis Therapeutics Holdings (COEP) EBITDA (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 5 years of EBITDA data on record, last reported at -$2.5 million in Q3 2025.

  • For Q3 2025, EBITDA fell 15.65% year-over-year to -$2.5 million; the TTM value through Sep 2025 reached -$13.2 million, down 321.44%, while the annual FY2024 figure was -$10.1 million, 130.76% down from the prior year.
  • EBITDA reached -$2.5 million in Q3 2025 per COEP's latest filing, up from -$4.5 million in the prior quarter.
  • Across five years, EBITDA topped out at $42.8 million in Q4 2022 and bottomed at -$15.7 million in Q1 2022.
  • Average EBITDA over 5 years is -$1.5 million, with a median of -$2.9 million recorded in 2024.
  • The widest YoY moves for EBITDA: up 413.59% in 2022, down 11004.82% in 2022.
  • A 5-year view of EBITDA shows it stood at -$13.6 million in 2021, then skyrocketed by 413.59% to $42.8 million in 2022, then tumbled by 67.61% to $13.9 million in 2023, then plummeted by 115.6% to -$2.2 million in 2024, then dropped by 14.56% to -$2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$2.5 million in Q3 2025, -$4.5 million in Q2 2025, and -$4.1 million in Q1 2025.